



Universiteit
Leiden
The Netherlands

Mutation-driven modulation of GPCR pharmacology in cancer: insights from adenosine and serotonin receptors

Feng, C.

Citation

Feng, C. (2026, January 27). *Mutation-driven modulation of GPCR pharmacology in cancer: insights from adenosine and serotonin receptors*. Retrieved from <https://hdl.handle.net/1887/4287696>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4287696>

Note: To cite this publication please use the final published version (if applicable).

Mutation-Driven

Modulation of GPCR Pharmacology in Cancer:

Insights from Adenosine and Serotonin Receptors

Cover design: Chenlin Feng

Thesis lay-out: Chenlin Feng

Printing: ProefschriftMaken – the Netherlands

© Copyright, Chenlin Feng, 2025

ISBN: 978-94-6534-103-3

All rights reserved. No part of this book may be reproduced in any form or by any means without permission of the author.

Mutation-Driven

Modulation of GPCR Pharmacology in Cancer:

Insights from Adenosine and Serotonin Receptors

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van (waarnemend) rector magnificus,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 27 Januari 2026
klokke 10:00 uur

door
Chenlin Feng
geboren te Luoyang, China
in 1992

Promotors:

Prof.dr. L.H. Heitman

Prof.dr. E.H.J. Danen

Promotiecommissie:

Prof.dr. M. van Eck

Prof.dr. E.C.M. de Lange

Prof.dr. A.P. IJzerman

Dr. S.E. Le Dévédec

Prof.dr. M. J. Smit (Vrije Universiteit Amsterdam)

Prof.dr. D. Guo (Xuzhou Medical University)

The research described in this thesis was performed at the division of Medicinal Chemistry and the division of Cell Systems and Drug Safety of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands). The research was financially supported by China Scholarship Council (CSC 201906210052) and ONCODE Institute.

Table of contents

Chapter 1	General introduction	7
Chapter 2	Review: GPCR-G protein signaling and its mutational landscape in cancer – driver or passenger	11
Chapter 3	Effects of cancer-associated mutations of the adenosine A _{2A} AR on ligand binding affinity and receptor function	37
Chapter 4	Kinetic profiling of novel A _{2A} AR agonists and antagonists leads to finely tuned ligand binding for cancer-associated mutants	61
Chapter 5	Exploring the role of adenosine A _{2A} AR and A _{2B} AR in cancer cell growth regulation	73
Chapter 6	The effect of cancer-associated mutations on ligand binding and receptor function – a case for the 5-HT _{2C} receptor	95
Chapter 7	Conclusions and future perspectives	113
	Summary	123
	Nederlandse samenvatting	125
	List of publications	127
	Curriculum vitae	128
	Acknowledgements	129